SAFE-HER

SAFE-HER

ROCHE SAFE-HER A Phase – III Prospective, Two-Cohort
Non-Randomized, Multi-Center,Multinational, Open Label study to assess the safety of Assisted and Operable HER2-Positive early Breast Cancer.


A safety and tolerability study of Assisted and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in patients with early HER-2 Positive Breast Cancer.